SEC Company Response from SOLIGENIX, INC. (SNGX) (CIK 0000812796) (SNGX) — Apr 15, 2009
SOLIGENIX, INC. (SNGX) (CIK 0000812796)
Date: April 15, 2009 · CIK: 0000812796 · Accession: 0000812796-09-000034
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-157322
Letter
accelerationrequst.htm
DOR BioPharma, Inc. 29 Emmons Drive, Suite C-10, Princeton, New Jersey
April 15,
Via EDGAR and Facsimile (202) 772-9217
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-4561
Attn: Jeffrey P. Riedler
Re: DOR BioPharma, Inc.
Pre-Effective Amendment No. 1 to Form S-1 Registration Statement
Filed April 14, 2009
File No. 333-157322
Ladies and Gentlemen:
The undersigned hereby respectfully requests, pursuant to Rule 461 of the Securities Act of 1933, as amended, that Pre-Effective Amendment No. 1 to Form S-1 Registration Statement filed by DOR BioPharma, Inc. (the “Company”) with the United States Securities and Exchange Commission (the “Commission”) on April 14, 2009 (File No. 333-157322) be declared effective as of 4:00 p.m., Eastern Time, on Friday, April 17, 2008, or as soon thereafter as possible.
The undersigned hereby acknowledges that (i) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very
truly yours,
DOR
BioPharma, Inc.
Show Raw Text
CORRESP
1
filename1.htm
accelerationrequst.htm
DOR
BioPharma, Inc. 29 Emmons Drive, Suite C-10, Princeton, New Jersey
08540
April 15,
2009
Via EDGAR and Facsimile
(202) 772-9217
Division
of Corporation Finance
United
States Securities and Exchange Commission
100 F
Street, N.E.
Washington,
D.C. 20549-4561
Attn: Jeffrey
P. Riedler
Re: DOR
BioPharma, Inc.
Pre-Effective Amendment No. 1 to Form
S-1 Registration Statement
Filed April 14, 2009
File No. 333-157322
Ladies
and Gentlemen:
The
undersigned hereby respectfully requests, pursuant to Rule 461 of the Securities
Act of 1933, as amended, that Pre-Effective Amendment No. 1 to Form S-1
Registration Statement filed by DOR BioPharma, Inc. (the “Company”) with the
United States Securities and Exchange Commission (the “Commission”) on April 14,
2009 (File No. 333-157322) be declared effective as of 4:00 p.m., Eastern Time,
on Friday, April 17, 2008, or as soon thereafter as possible.
The
undersigned hereby acknowledges that (i) should the Commission or the staff,
acting pursuant to delegated authority, declare the filing effective, it does
not foreclose the Commission from taking any action with respect to the filing;
(ii) the action of the Commission or the staff, acting pursuant to delegated
authority, in declaring the filing effective, does not relieve the Company from
its full responsibility for the adequacy and accuracy of the disclosure in the
filing; and (iii) the Company may not assert the declaration of effectiveness as
a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.
Very
truly yours,
DOR
BioPharma, Inc.
By: /s/ Christopher J.
Schaber
Christopher
J. Schaber, Ph.D.
President
and Chief Executive Officer
cc: Leslie
J. Croland, Esq.